Mode
Text Size
Log in / Sign up
Phase 3 N=188 Randomized Single-blind Prevention

Low Vision Depression Prevention Trial for Age Related Macular Degeneration

Age-related Macular Degeneration · Depression

Enrolled (actual)
188
Serious AEs
30.9%
Results posted
Nov 2014
Primary outcome: Primary: Depression — 11; 18; 5; 11 participants — p=.067

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
BA-LVR (Behavioral); ST-LVR (Behavioral)
Age
Older Adult · 65+ yrs
Sex
All
Sponsor
Thomas Jefferson University
Primary completion
Jan 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Depression
11; 18; 5; 11; 6; 7 .067
SECONDARY
Vision Function: Distance Activities
0.31; 1.12 .75
SECONDARY
Quality of Life: Dependency
2.07; 5.54 .68
SECONDARY
Vision Function: Near Activities
4.78; 2.36 .34
SECONDARY
Quality of Life: Mental Health
2.23; 4.25 .68
SECONDARY
Quality of Life: Role Functioning
2.33; .93 .68
SECONDARY
Quality of Life: Social Function
-.38; -2.00 .68

Summary

This randomized, controlled clinical trial, the Low Vision Depression Prevention TriAL (VITAL), will test the efficacy of collaborative low vision rehabilitation (LVR) to prevent depressive disorders in Age-Related Macular Degeneration (AMD). In this innovative intervention, a low vision occupational therapist collaborates with a low vision optometrist to develop and implement a care plan based on a subject's vision status, rehabilitation potential, and personal rehabilitation goals. An independent rater masked to treatment assignment will assess depressive disorders meeting DSM-IV criteria (primary outcome) and targeted vision function and vision-related quality of life (secondary outcomes) at baseline and then at 4 months to evaluate short-term effects (main trial end point) and at 12 months to evaluate long-term effects.

Eligibility Criteria

Inclusion Criteria

  • Age at least 65 years old
  • Bilateral AMD
  • Subthreshold depressive symptoms
  • At least 1 vision goal that is important yet difficult to carry out

Exclusion Criteria

  • Uncontrolled glaucoma, diabetic retinopathy, corneal dystrophy, or cataracts for which surgery within 6 months is likely will be exclusionary conditions
  • Current diagnosis of depression
  • Cognitive impairment
  • Life-threatening illness or any other health conditions that interferes with study activities.
  • Patients who have received low vision rehabilitation or home-based OT in the preceding 12 months will be excluded.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00769015). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search